by Chris Wack
SciSparc Ltd. on Tuesday said it has seen positive safety profile results from its joint pre-clinical trial with Clearmind, testing a proprietary combination of SciSparc’s CannAmide with MEAI, Clearmind’s psychedelic molecule, for alcohol consumption.
A histopathology assessment was performed on multiple organs from all experiment groups to determine the safety of the proprietary combination of MEAI and CannAmide versus controls that were not exposed to alcohol. The results indicated a high safety profile of the combination treatment, with no treatment-related changes observed.
SciSparc said it plans to explore the safety and efficacy of combining its technology with Clearmind’s novel molecule.
The previously announced successful results showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption in treated animals, with additional significant effects upon combination of cannaamide with a low suboptimal MEAI dose.
Shares of SciSparc rose 28% to $2.51 in premarket trading.
Write to Chris Wack at [email protected]
Credit: www.marketwatch.com /